Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Completed · Phase 1/Phase 2

Conditions studied: Metastatic Prostate Cancer

In brief

The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2 drugs.

Key facts

Study ID

NCT00439270

Run by

Bristol-Myers Squibb

People needed

49

Starts

2007-07-01

Expected to finish

2013-01-01

Last updated by the study team

2014-03-28

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• University of Chicago — Chicago, Illinois, United States
• Springfield Clinic — Springfield, Illinois, United States
• Hematology-Oncology Associates Of Rockland — Nyack, New York, United States
• Duke University — Durham, North Carolina, United States
• The University Of Texas Md Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.